Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genix PharmaceuticalsGENPF Earnings per Share (Diluted) is $-0.01 as of Apr. 2026. The stock has 3 warning signs investors should review. Among 784 Drug Manufacturers companies, Genix Pharmaceuticals ranks better than 65.69% on this metric.
Genix Pharmaceuticals (OTCPK:GENPF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Genix Pharmaceuticals Earnings per Share (Diluted) Related Terms
Genix Pharmaceuticals Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Genix Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genix Pharmaceuticals Earnings per Share (Diluted) Chart
GENPF vs ZTS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genix Pharmaceuticals PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Genix Pharmaceuticals's PE Ratio falls into.
Genix Pharmaceuticals Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Genix Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Oct. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.01 mean?
Genix Pharmaceuticals (GENPF) has a Earnings per Share (Diluted) of $-0.01 as of Apr. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genix Pharmaceuticals and its competitors. According to the industry distribution chart, Genix Pharmaceuticals ranks #269 out of 784 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is Genix Pharmaceuticals' Earnings per Share (Diluted) too high?
Genix Pharmaceuticals' current Earnings per Share (Diluted) is $-0.01. Based on the distribution chart, Genix Pharmaceuticals ranks #269 out of 784 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Genix Pharmaceuticals' Earnings per Share (Diluted) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #269 out of 784 companies for Earnings per Share (Diluted). This puts Genix Pharmaceuticals in the upper half of its industry. The industry median Earnings per Share (Diluted) is 9.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.80, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current Earnings per Share (Diluted) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current Earnings per Share (Diluted) of $-0.01. The current Earnings per Share (Diluted) is $-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current Earnings per Share (Diluted) is $-0.01 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENPF has been successfully added to your 
